Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab may be more effective at extending survival in patients with NLPHL than the usual approach with rituximab.

Trial Details

NCT ID

NCT05886036

Phase

PHASE2

Sponsor

National Cancer Institute (NCI)

Status

RECRUITING

Cancer Type

Non-Hodgkin Lymphoma Lymphoma

Interventions

Biopsy Procedure
Biospecimen Collection
Bone Marrow Biopsy
Computed Tomography
Fludeoxyglucose F-18
Mosunetuzumab

Locations (sample)

Duarte, California, United States|34.13945,-117.97729
Aventura, Florida, United States|25.95648,-80.13921
Coral Gables, Florida, United States|25.72149,-80.26838
Coral Springs, Florida, United States|26.27119,-80.2706
Deerfield Beach, Florida, United States|26.31841,-80.09977

Key Eligibility Criteria

Histopathologically confirmed diagnosis of NLPHL as confirmed by local pathologist's expert review.
Untreated NLPHL: stage IB to IV according to Cotswolds. The proportion of patients with stages I or II treated with consolidative radiotherapy will…
Previously treated NLPHL, any stage.
According to the treating physician, the patient should not be observed and needs therapy, notably because of B-symptoms (unexplained fever \[tempe…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →